Facebook
X
LinkedIn
ForwardRadiopharmaceutical Therapies Webinar Series
Radiopharmaceutical therapies have been a breakthrough cancer treatment for tumors resistant to cytotoxic chemotherapy and many new radiopharmaceutical agents are in active development. Two newer FDA approved radiopharmaceutical agents 177Lu-Dotatate and 177Lu-PSMA-617 are being increasingly utilized in radiation oncology practices with many groups in academic and community settings starting theranostics programs. This webinar series will discuss advancements in radiopharmaceutical therapy, current indications, and challenging cases.
This series will be divided into two one-hour sessions, one focusing on 177Lu-Dotatate and the other on 177Lu-PSMA-617.
TOPICS COVERED
- Lu177-DOTATATE: Current Indications and Emerging Approaches
- Advancing Radiation Oncology Leadership in PSMA-Targeted Radiopharmaceutical Therapy
Please see the Program tab for the session descriptions and presenters.
This activity is available from March 17, 2026 through 11:59 pm Eastern time on March 16, 2028.
CME credit for the live event must be claimed by May 21, 2026.
Live Webinar Dates:
April 16, 2026 - 12:30 p.m. - 1:30 p.m. ET
April 21, 2026 - 5:15 p.m. - 6:15 p.m. ET
Target Audience
This activity is designed to meet the interests of radiation oncologists, medical oncologists, pathologists, surgeons, researchers, radiologists, nuclear medicine physicians and allied healthcare professionals interested in theranostic therapies for cancer treatment.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Understand current indications for cancer care and management of patients with radiopharmaceutical therapies.
- Gain insight into the complexities of patient management and discuss needs of starting a new radiopharmaceutical therapy program.
- Discuss challenges in patient management and future indications for radiopharmaceuticals.
Lu177-DOTATATE: Current Indications and Emerging Approaches
April 16, 2026 - 12:30 p.m. - 1:30 p.m. ET
- Neil K. Taunk, MD, MSCTS
- Moderator: Ravi Patel, MD, PhD
Lu177-DOTATATE is an important treatment in neuroendocrine tumors and a radiopharmaceutical therapy with established use and history. Failure to stay informed on this treatment may prevent specific patient groups from having access to this care. This webinar will discuss the basic compound and evolution of Lu177-DOTATATE. We will review current indications for therapy including the treatment of GEP-NETs and expected outcomes. Finally, we will discuss emerging indications for DOTATATE therapy as well as novel radionuclides utilized in current study.
Advancing Radiation Oncology Leadership in PSMA-Targeted Radiopharmaceutical Therapy
April 21, 2026 - 5:15 p.m. - 6:15 p.m. ET
- Mallika Marar, MD, MBA
- Moderator: Ravi Patel, MD, PhD
Since its initial FDA approval in 2022, 177Lu-PSMA-617 targeted radiopharmaceutical therapy (RPT) is now well-established within the treatment paradigm for metastatic castration-resistant prostate cancer. Radiation oncologists are eligible to become authorized users overseeing RPT and are increasingly incorporating 177Lu-PSMA-617 into clinical practice across academic and community settings. This webinar will review current indications for 177Lu-PSMA-617 and practical considerations related to PSMA-directed RPTs including practice building and multidisciplinary patient management. Applications of pre-treatment molecular imaging with PSMA PET as part of the Theragnostic treatment paradigm will be discussed along with post-treatment imaging including SPECT. The session will also explore topics related to further improving on prostate cancer clinical outcomes with PSMA-directed RPTs including ongoing clinical trials, dosimetry, and combination therapy including with external beam radiotherapy. A discussion of challenging clinical scenarios related to applying 177Lu-PSMA-617 in the clinic will also be included.
Moderator:
- Ravi Patel, MD, PhD, is employed by University of Pittsburgh School of Medicine. Dr. Patel receives grant/research funding from Voximetry and Merck. Dr. Patel previously served on the advisory board of Lantheus [relationship ended 10/27/2025] and GE Healthcare [relationship ended 11/6/2025].
Speakers:
- Mallika Marar, MD, MBA, is employed by Stanford University. Dr. Marar receives salary support from Novartis. Dr. Marar previously received salary support from Reflexion [relationship ended 10/10/2025].
- Neil Taunk, MD, MSCTS, is employed by the University of Pennsylvania. Dr. Taunk receives grant/research funding from Point BioPharma/Eli Lilly and Varian Medical Systems. Dr. Taunk receives compensation/payment from Boston Scientific and Point BioPharma/Eli Lilly. Dr. Taunk receives honoraria from Novartis, GE Healthcare, Boston Scientific and Point BioPharma/Eli Lilly.
Planners:
- Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Continuing education credits for this activity must be claimed by May 21, 2026 by completing the evaluation.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 2.00 Certificate of AttendanceThis activity was designated for 2.00 AMA PRA Category 1 Credit™.
Price
Course fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Member: $199
Member-in-training: $99
Member Student/Grad Student/PGY: $99
Member Postdoctoral Fellow: $99
Nonmember: $299
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until March 16, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.